- Home
- ARQT vs IHS Comparison
ARQT vs IHS Comparison
Compare ARQT & IHS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- IHS
- Stock Information
- Founded
- ARQT 2016
- IHS 2001
- Country
- ARQT United States
- IHS United Kingdom
- Employees
- ARQT N/A
- IHS N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- IHS Telecommunications Equipment
- Sector
- ARQT Health Care
- IHS Telecommunications
- Exchange
- ARQT Nasdaq
- IHS Nasdaq
- Market Cap
- ARQT 1.7B
- IHS 1.9B
- IPO Year
- ARQT 2020
- IHS 2021
- Fundamental
- Price
- ARQT $13.82
- IHS $5.77
- Analyst Decision
- ARQT Strong Buy
- IHS Strong Buy
- Analyst Count
- ARQT 6
- IHS 6
- Target Price
- ARQT $18.80
- IHS $9.67
- AVG Volume (30 Days)
- ARQT 1.9M
- IHS 895.1K
- Earning Date
- ARQT 08-13-2025
- IHS 08-12-2025
- Dividend Yield
- ARQT N/A
- IHS N/A
- EPS Growth
- ARQT N/A
- IHS N/A
- EPS
- ARQT N/A
- IHS N/A
- Revenue
- ARQT $212,819,000.00
- IHS $1,733,125,000.00
- Revenue This Year
- ARQT $61.15
- IHS $0.63
- Revenue Next Year
- ARQT $37.98
- IHS $4.82
- P/E Ratio
- ARQT N/A
- IHS N/A
- Revenue Growth
- ARQT 100.03
- IHS N/A
- 52 Week Low
- ARQT $7.86
- IHS $2.44
- 52 Week High
- ARQT $17.75
- IHS $6.30
- Technical
- Relative Strength Index (RSI)
- ARQT 50.73
- IHS 53.28
- Support Level
- ARQT $12.97
- IHS $5.50
- Resistance Level
- ARQT $13.84
- IHS $5.92
- Average True Range (ATR)
- ARQT 0.61
- IHS 0.22
- MACD
- ARQT 0.02
- IHS -0.02
- Stochastic Oscillator
- ARQT 51.64
- IHS 62.75
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About IHS IHS Holding Limited
IHS Holding Ltd is an independent owner, operator, and developer of shared telecommunications infrastructure. The company provides telecommunications infrastructure to its customers, who are MNOs, who in turn provide wireless voice and data services to their end-users. Its geographical segments are Nigeria, Sub-Saharan Africa, the Middle East and North Africa (MENA), and Latin America (Latam). The majority of its revenue is derived from Nigeria.